Sonda partners with university on ERP courses

Friday, February 11, 2011

Sonda Procwork, a Brazilian unit of Chilean IT systems integrator Sonda IT, is partnering with Caixas do Sul University (UCS) to design extension courses centered on enterprise resource planning (ERP) systems, the company said in a statement.

Sonda expects the agreement to bolster the IT workforce in the southern state of Rio Grande do Sul, where corporate demand for management solutions is growing. The company suggested it too would benefit from a more qualified pool of candidates.

"Caxias do Sul is an important industrial center, and increasingly there is a shortage of skilled labor," said the UCS computing and IT center extension coordinator Daniel Antônio Faccin. "With the offering of courses, our goal is to expand the capacity to provide service and thus stimulate the local economy."

Start your 15 day free trial now!


Already a subscriber? Please, login

Sonda professionals will oversee the extension courses, the first of which will begin February 14 and focus on accounting and finance processes. Sonda maintains a presence in Rio Grande do Sul through a regional office in the capital of Porto Alegre. The company has 31 offices across Brazil and more than 20 years in the national market.


Brazilian pharmaceutical firm Prati-Donaduzzi grew revenues 30% in the year since Sonda Procwork installed its SAP-based ERP system, the latter company said in a statement.

Prati-Donaduzzi invested 1.8mn reais (US$1.08mn) in the project.

The software implemented by Sonda allowed Prati-Donaduzzi to consolidate the accounting and finance operations of its four affiliates, an important step in meeting new government requirements for tax reporting. The company increased its invoice generation capacity by 90%.

Prati-Donaduzzi also credited the ERP with enhancing productivity, visibility and evaluation processes, as well as reducing IT maintenance and support costs.

SAP Brasil VP André Petroucic said the Prati-Donaduzzi project should help solidify his company's foothold in the pharmaceutical sector.